Seungbong Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seungbong Han has a total of 279 co-authors. Here are the top co-authors by number of shared publications:
- Gyung-Min Park
Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
15 shared publications - Byoung-Gie Kim
Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
10 shared publications - Dae Hoon Jeong
Department of Obstetrics and Gynecology, Busan Paik Hospital, Paik Institute for Clinical Research, College of Medicine, Inje University, Busan, Korea
10 shared publications - Eric Pujade-Lauraine
Association de Recherche sur les CAncers dont GYnécologiques (ARCAGY)-GINECO, Paris, France
10 shared publications - Hae Seo
Department of Biomedical Sciences, Korea University College of Medicine, Seoul, South Korea
10 shared publications - Hyun-Woong Cho
Department of Obstetrics and Gynecology, Asan Medical Center, Seoul, Republic of Korea
10 shared publications
Latest Publications
- 31 October 2026
- Published by The Korean Statistical Society in Korean Journal of Applied Statistics
- Vol. 39 (5) , 455-475
Extracting individual patient data and its application to the restricted mean survival time model: a simulation study
Jooyi Jung, Seungbong Han. Korean J Appl Stat 2026;39:455-75. https://doi.org/10.5351/KJAS.2026.39.5.455
- 31 October 2026
- Published by The Korean Statistical Society in Korean Journal of Applied Statistics
- Vol. 39 (5) , 455-475
Extracting individual patient data and its application to the restricted mean survival time model: a simulation study
Jooyi Jung, Seungbong Han. Korean J Appl Stat 2026;39:455-75. https://doi.org/10.5351/KJAS.2026.39.5.455
- Open Access
- 15 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Mortality Risk in Steatotic Liver Disease Stratified by Cardiometabolic Risk Factors and Alcohol Consumption: A Nationwide Cohort Study
Yewan Park, Jooyi Jung, Seungbong Han, Hyeyeon Hong, Gi-Ae Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260003
- 15 October 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
Open AccessMortality Risk in Steatotic Liver Disease Stratified by Cardiometabolic Risk Factors and Alcohol Consumption: A Nationwide Cohort Study
Yewan Park, Jooyi Jung, Seungbong Han, Hyeyeon Hong, Gi-Ae Kim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl260003
- Open Access
- 25 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Integrated proteomics–driven discovery of synovial fluid biomarkers reflecting structural damage and pain in knee osteoarthritis
- 25 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessIntegrated proteomics–driven discovery of synovial fluid biomarkers reflecting structural damage and pain in knee osteoarthritis
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
KM curve according to subgroups
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
KM curve according to subgroups
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Best response to most recent platinum-based chemotherapy according to progression during or after previous PARPi
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Best response to most recent platinum-based chemotherapy according to progression during or after previous PARPi
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Flowchart Showing the Patient Enrollment Criteria
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Flowchart Showing the Patient Enrollment Criteria
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
A study Representativeness Table
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
A study Representativeness Table
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Chemotherapy and targeted therapies received as first subsequent treatment (FST) following progression
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
Chemotherapy and targeted therapies received as first subsequent treatment (FST) following progression
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
KM curve according to HR-related features
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor
KM curve according to HR-related features